European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078)

European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078)

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Rasmussen, N, Jayne, D, Abramowicz, D, Andrassy, K, Bacon, P, Cohen Tervaert, J, Dadonlené, J, Feighery, C, Van Es, L, Ferrario, F, Gaskin, G, Gregorini, G, De Groot, K, Gross, W, Grönhagen-Riska, C, Guillevin, L, Hagen, E, Heigl, Z, Hermans, J, Kallenberg, C, Landais, P, Lesavre, P, Lockwood, C, Luqmani, R, Mirapeix, E
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	1995

Míreanna comhchosúla

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
de réir: Suppiah, R, et al.
Foilsithe / Cruthaithe: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
de réir: Suppiah, R, et al.
Foilsithe / Cruthaithe: (2011)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
de réir: De Groot, K, et al.
Foilsithe / Cruthaithe: (2005)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis.
de réir: de Groot, K, et al.
Foilsithe / Cruthaithe: (2003)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
de réir: Hellmich, B, et al.
Foilsithe / Cruthaithe: (2007)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
de réir: Yew, S, et al.
Foilsithe / Cruthaithe: (2012)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
de réir: Yew, S, et al.
Foilsithe / Cruthaithe: (2012)

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
de réir: Mukhtyar, C, et al.
Foilsithe / Cruthaithe: (2008)

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (2001)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
de réir: Jones, R, et al.
Foilsithe / Cruthaithe: (2009)

Eular recommendations for vasculitis
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (2007)

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
de réir: Jayne, DR, et al.
Foilsithe / Cruthaithe: (1997)

Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (2000)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2013)

Outcome in systemic vasculitis.
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (1998)

The European Vasculitis Society 2016 meeting report
de réir: Bajema, IM, et al.
Foilsithe / Cruthaithe: (2017)

Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. A European, multi-centre randomized controlled trial: long-term follow-up
de réir: Harper, L, et al.
Foilsithe / Cruthaithe: (2011)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2015)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2013)

EULAR recommendations for the management of large vessel vasculitis.
de réir: Mukhtyar, C, et al.
Foilsithe / Cruthaithe: (2009)

Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis.
de réir: Adu, D, et al.
Foilsithe / Cruthaithe: (1997)

Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial
de réir: Harper, L, et al.
Foilsithe / Cruthaithe: (2009)

The future of damage assessment in vasculitis.
de réir: Seo, P, et al.
Foilsithe / Cruthaithe: (2007)

Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
de réir: Jennifer J. Y. Lee, et al.
Foilsithe / Cruthaithe: (2019-06-01)

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.
de réir: Basu, N, et al.
Foilsithe / Cruthaithe: (2010)

Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
de réir: Jayne, D, et al.
Foilsithe / Cruthaithe: (1999)

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
de réir: Mukhtyar, C, et al.
Foilsithe / Cruthaithe: (2007)

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
de réir: de Groot, K, et al.
Foilsithe / Cruthaithe: (2009)

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (1994)

EULAR recommendations for the management of primary small and medium vessel vasculitis.
de réir: Mukhtyar, C, et al.
Foilsithe / Cruthaithe: (2009)

Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2013)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
de réir: Suppiah, R, et al.
Foilsithe / Cruthaithe: (2011)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
de réir: Robson, J, et al.
Foilsithe / Cruthaithe: (2014)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases
de réir: Ponte, C, et al.
Foilsithe / Cruthaithe: (2014)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.
de réir: Ponte, C, et al.
Foilsithe / Cruthaithe: (2014)

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
de réir: Luqmani, R, et al.
Foilsithe / Cruthaithe: (2009)

Systemic vasculitis.
de réir: Jordan, K, et al.
Foilsithe / Cruthaithe: (2002)

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
de réir: Mukhtyar, C, et al.
Foilsithe / Cruthaithe: (2008)

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
de réir: Merkel, P, et al.
Foilsithe / Cruthaithe: (2011)